Jaron M. Acker, Madison, WI (US); Craig R. Tolmie, Stoughton, WI (US); Robin Roehl, Janesville, WI (US); Jeffrey Schmidt, Fitchburg, WI (US); and Jeff Milsap, Cambridge, WI (US)
Assigned to Mallinckrodt Pharmaceuticals Ireland Limited, Dublin (IE)
Filed by Mallinckrodt Pharmaceuticals Ireland Limited, Dublin (IE)
Filed on Feb. 17, 2022, as Appl. No. 17/674,198.
Application 17/674,198 is a continuation of application No. 16/825,840, filed on Mar. 20, 2020, granted, now 11,285,280.
Application 16/825,840 is a continuation of application No. 16/217,969, filed on Dec. 12, 2018, granted, now 10,894,135, issued on Jan. 19, 2021.
Application 16/217,969 is a continuation of application No. 14/709,298, filed on May 11, 2015, granted, now 10,201,674, issued on Feb. 12, 2019.
Claims priority of provisional application 61/991,032, filed on May 9, 2014.
Claims priority of provisional application 61/991,083, filed on May 9, 2014.
Claims priority of provisional application 61/991,028, filed on May 9, 2014.
Prior Publication US 2022/0168520 A1, Jun. 2, 2022
20. A method for administering therapeutic gas to a patient comprising obtaining identifying information from a gas source identifier, wherein the gas source identifier is affixed to a compressed gas cylinder with an initial gas pressure of 2000 psi to 5000 psi having an NO concentration of a 4000 ppm to 10000 ppm, and wherein the compressed gas cylinder weighs less than 15 pounds, and the compressed gas cylinder comprises a gas source valve; communicating a signal to the gas source valve to transition to an open state.
